David Dadiomov

Title(s)Associate Professor of Clinical Pharmacy (Clinical Track)
SchoolUSC School of Pharmacy
Address1969 Zonal Avenue
Health Sciences Campus
Los Angeles CA 90089-9121
Phone+1 323 442 1414
vCardDownload vCard

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Reply to 'Methodological concerns and interpretative limitations of assessing subjective effects of ketamine'. Npj Ment Health Res. 2026 Sep 22; 5(1). Dahan JDC, Dadiomov D, Bostoen T, Dahan A. PMID: 42773206; PMCID: PMC13598091.
      View in: PubMed   Mentions:
    2. Board-certified psychiatric pharmacists in substance use disorder treatment: Integration, services, and outcomes across care settings. Ment Health Clin. 2026 Jun; 16(3):117-124. Vallabh A, Abelleira A, Douglass AR, Gutierrez CA, Maister A, Miskle B, Moeller KE, Salwan A, Waters K, Dadiomov D. PMID: 42239826; PMCID: PMC13229528.
      View in: PubMed   Mentions:
    3. The Role of Board-Certified Psychiatric Pharmacists in Substance Use Disorder Care. Subst Use Addctn J. 2026 01; 47(1):5-8. Vallabh A, Abelleira A, Douglass AR, Gutierrez CA, Maister A, Miskle B, Moeller KE, Salwan A, Waters K, Dadiomov D. PMID: 40720337.
      View in: PubMed   Mentions:    Fields:    
    4. Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel. Drug Alcohol Depend Rep. 2025 Sep; 16:100360. Varisco TJ, Thornton D, Hussain T, Fish H, Bolin J, Dadiomov D, Essien EJ, Wanat MA, Ginsburg D, Waggener J, Bratberg JP, DiPaula B, Hill LG, PhARM-OUD Working Group. PMID: 40727322; PMCID: PMC12301831.
      View in: PubMed   Mentions: 1  
    5. Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination. Ment Health Clin. 2025 Apr 01; 15(2):43-50. Roth W, Dadiomov D. PMID: 40224513; PMCID: PMC11993145.
      View in: PubMed   Mentions:
    6. Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome. Npj Ment Health Res. 2024 Oct 06; 3(1):45. Dahan JDC, Dadiomov D, Bostoen T, Dahan A. PMID: 39369173; PMCID: PMC11455954.
      View in: PubMed   Mentions: 2  
    7. Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy. Arch Public Health. 2024 Apr 25; 82(1):58. Varisco TJ, Fish H, Bolin J, Dadiomov D, Hill LG, Essien EJ, Wanat MA, Ginsburg D, Waggener J, Yazdanfard S, Song J, Chi W, Thornton D. PMID: 38664777; PMCID: PMC11044383.
      View in: PubMed   Mentions: 1  
    8. Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effects. Ther Adv Drug Saf. 2023; 14:20420986231213173. Roth W, Dadiomov D, Chu M. PMID: 38074415; PMCID: PMC10702410.
      View in: PubMed   Mentions:
    9. Dissociating the Clinical Role and Economic Value of Intranasal Esketamine. J Manag Care Spec Pharm. 2020 Jan; 26(1):20-22. Dadiomov D. PMID: 31880233; PMCID: PMC10391094.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. The effects of ketamine on suicidality across various formulations and study settings. Ment Health Clin. 2019 Jan; 9(1):48-60. Dadiomov D, Lee K. PMID: 30627504; PMCID: PMC6322816.
      View in: PubMed   Mentions: 20  
    11. Using the LACE Score as a Predictor of Clinical Outcomes in Patients Referred for Inpatient Palliative Care Consultation: A Single-Center Experience. Am J Hosp Palliat Care. 2026 Mar; 43(3):305-309. Dadiomov D, Keefer P, Smith MA. PMID: 30064238.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    David's Networks
    Concepts (28)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-64-g4ee1c7b9 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.